106 related articles for article (PubMed ID: 27187160)
1. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study.
Elkarta A; Awadalla A; El-Hefnawy A; Mosbah A; Abolenein H; Shokeir A
Clin Genitourin Cancer; 2024 Apr; 22(2):38-46.e1. PubMed ID: 37758560
[TBL] [Abstract][Full Text] [Related]
3. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
Beckabir W; Wobker SE; Damrauer JS; Midkiff B; De la Cruz G; Makarov V; Flick L; Woodcock MG; Grivas P; Bjurlin MA; Harrison MR; Vincent BG; Rose TL; Gupta S; Kim WY; Milowsky MI
Eur Urol; 2024 Mar; 85(3):242-253. PubMed ID: 38092611
[TBL] [Abstract][Full Text] [Related]
4. Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective.
Kim JM; Choi E; Sung SH; Jo J; Lee DH; Park S
Clin Genitourin Cancer; 2024 Apr; 22(2):224-236. PubMed ID: 38042728
[TBL] [Abstract][Full Text] [Related]
5. Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer.
Kohut-Jackson A; Orf J; Barresi D; Davaro F; Hamilton Z
Urol Oncol; 2024 May; 42(5):160.e25-160.e31. PubMed ID: 38238117
[TBL] [Abstract][Full Text] [Related]
6. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Beckabir W; Zhou M; Lee JS; Vensko SP; Woodcock MG; Wang HH; Wobker SE; Atassi G; Wilkinson AD; Fowler K; Flick LM; Damrauer JS; Harrison MR; McKinnon KP; Rose TL; Milowsky MI; Serody JS; Kim WY; Vincent BG
Nat Commun; 2024 May; 15(1):4448. PubMed ID: 38789460
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.
Hermans TJN; Voskuilen CS; van der Heijden MS; Schmitz-Dräger BJ; Kassouf W; Seiler R; Kamat AM; Grivas P; Kiltie AE; Black PC; van Rhijn BWG
Urol Oncol; 2018 Sep; 36(9):413-422. PubMed ID: 29128420
[TBL] [Abstract][Full Text] [Related]
8. Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy.
Wang Z; He W; Ying Y; Wang M; Chen Q; Zhang Z; Zeng S; Xu C
Clin Genitourin Cancer; 2024 Apr; 22(2):201-209.e7. PubMed ID: 37989709
[TBL] [Abstract][Full Text] [Related]
9. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
[TBL] [Abstract][Full Text] [Related]
10. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
[TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Lu YT; Plets M; Morrison G; Cunha AT; Cen SY; Rhie SK; Siegmund KD; Daneshmand S; Quinn DI; Meeks JJ; Lerner SP; Petrylak DP; McConkey D; Flaig TW; Thompson IM; Goldkorn A
Eur Urol Oncol; 2023 Oct; 6(5):516-524. PubMed ID: 37087309
[TBL] [Abstract][Full Text] [Related]
12. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Reike MJ; de Jong JJ; Bismar TA; Boorjian SA; Mian OY; Wright JL; Dall'Era MA; Kaimakliotis HZ; Lotan Y; Boormans JL; Black PC; Gibb EA
Urol Oncol; 2024 Jun; 42(6):177.e5-177.e14. PubMed ID: 38480079
[TBL] [Abstract][Full Text] [Related]
13. Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study.
Anan G; Hatakeyama S; Fujita N; Iwamura H; Tanaka T; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ito H; Yoshikawa K; Kawaguchi T; Sato M; Ohyama C
Oncotarget; 2017 Oct; 8(49):86130-86142. PubMed ID: 29156782
[TBL] [Abstract][Full Text] [Related]
14. Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer.
Kim Y; Ju H; Yoo SY; Jeong J; Heo J; Lee S; Park JM; Yoon SY; Jeong SU; Lee J; Yun H; Ryu CM; Lee J; Nam YJ; Kwon H; Son J; Jeong G; Oh JH; Sung CO; Jeong EM; An J; Won S; Hong B; Lee JL; Cho YM; Shin DM
Cell Rep Med; 2023 Oct; 4(10):101224. PubMed ID: 37797616
[TBL] [Abstract][Full Text] [Related]
15. CD19
Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
[TBL] [Abstract][Full Text] [Related]
16. Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture.
Mi H; Bivalacqua TJ; Kates M; Seiler R; Black PC; Popel AS; Baras AS
Cell Rep Med; 2021 Sep; 2(9):100382. PubMed ID: 34622225
[TBL] [Abstract][Full Text] [Related]
17. Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
Hensley PJ; Seiler R; Herr H; Mouw KW; Iyer G; Dyrskjøt L; Nawroth R; Goebell P; Schmitz-Drager B; Todenhofer T; Black PC; Kamat AM; Williams SB
Urol Oncol; 2023 Jul; 41(7):307-312. PubMed ID: 36702704
[TBL] [Abstract][Full Text] [Related]
18. The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy.
Ho MD; Black AJ; Zargar H; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Montgomery JS; Yu EY; Xylinas E; Kassouf W; Dall'Era MA; Vasdev N; Sridhar SS; McGrath JS; Aning J; Holzbeierlein JM; Thorpe AC; Shariat SF; Wright JL; Morgan TM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Can Urol Assoc J; 2023 Oct; 17(10):301-309. PubMed ID: 37851909
[TBL] [Abstract][Full Text] [Related]
19. Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer.
Ikarashi D; Kitano S; Tsuyukubo T; Yamashita M; Matsuura T; Maekawa S; Kato R; Kato Y; Kanehira M; Takata R; Sugai T; Obara W
Sci Rep; 2024 Jan; 14(1):1442. PubMed ID: 38228697
[TBL] [Abstract][Full Text] [Related]
20. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy.
Mo Q; Li R; Adeegbe DO; Peng G; Chan KS
Commun Biol; 2020 Dec; 3(1):784. PubMed ID: 33335285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
